Skip to main content

View full-text article in PMC

. 2021 Mar 24;12(3):164–182. doi: 10.5306/wjco.v12.i3.164

Table 5.

Pivotal Phase III studies of poly adenosine diphosphate ribose polymerase inhibitors in patients with germline BRCA1/BRCA2 mutations

Trial	n	Drug	Median PFS (mo) 1^st line	Media PFS (mo) ≥ 1 line	Media OS (mo) 1^st line	Media OS (mo) ≥ 1 line	Ref.
OLYMPIAD	296	Olaparib		7.3		19.3	Robson et al[67], 2017
EMBRCA	431	Talazoparib		8.6		19.6	Litton et al[69], 2020
BROCADE3 (1^st line)	337	Veliparib	14.5		33.5		Bardia et al[77], 2020

PFS: Progression free survival; OS: Overall survival.